In honor of families and caregivers of those living with #Huntingtondisease, throughout July we will be sharing insights from caregiver Sarina. You can read her #LifeWithHD story here: https://lnkd.in/d-gFhGBd #HD
Prilenia
Biotechnology Research
Boston, Massachusetts 5,513 followers
Dedicated to developing new treatments for neurodegenerative diseases and neurodevelopmental disorders.
About us
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.
- Website
-
https://www.prilenia.com/
External link for Prilenia
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
Boston, Massachusetts, US
-
Get directions
Herzliya, Israel, IL
-
Get directions
Naarden, NL
Employees at Prilenia
Updates
-
The NIH NINDS-sponsored ACT for ALS Expanded Access to Pridopidine Protocol (EAP), led by the Mass General Brigham hospital Sean M. Healey & AMG Center for ALS, is available at treating sites across the U.S. for up to 200 #ALS individuals who are not eligible for other clinical trials. Those accepted into the EAP may be treated with pridopidine for up to two years. Click here to find more information on eligibility criteria and your nearest site: https://lnkd.in/dtmgsEvh
-
‘Alone we are rare, together we are strong.’ Getting together for a great cause like the Huntington Disease Society of America (HDSA) Boston Team Hope Walk helps make us stronger! #HuntingtonsDisease
-
-
Global ALS Awareness Day is a day where we recognize everyone impacted by ALS/MND. Thank you to those in the ALS community who continue to drive research and awareness for this rare disease. #ALSMNDWithoutBorders #ALS https://lnkd.in/g3hTiWHs
Global Day
https://www.als-mnd.org
-
Excited to be at #ENCALS 2024 in Stockholm, Sweden, June 17-20. Our CMO, Dr. Jina Swartz, and Medical Director of Clinical Development, Andrés Cruz-Herranz will both be attending, come say hi if you spot them. #ALS #ALSAwareness
-
-
This Father's Day we send our love to all the dads, both past and present, who have or are dealing with #HD or #ALS for themselves or a loved one. Learn more: https://lnkd.in/dFiyrtEp
Living in a Family with HD
hdyo.org
-
Health isn’t just about the things you can see. During June’s #MensHealthMonth we want to recognize all the men whose mental health may be equally impacted dealing with #HD, #ALS, or other rare neurodegenerative diseases. #HuntingtonsDisease
-
-
EverythingALS "#Pridopidine for treatment of #ALS" webinar with Prilenia's Michael Hayden and Henk Schuring, June 12th, 2024 | 4PM PT, 7PM ET - to register: https://lnkd.in/d_u9NnUD
-